Louise Farley explains that the Patient Capital Review didn’t change much for Deepbridge as the company had previously had a knowledge-intensive focus. She covers the underlying investments in Deepbridge’s portfolio, deal flow and expansion into new specialist sub-sectors of tech and life science. Farley also explains the company’s support philosophy for investee companies.